Hikma Expands US Portfolio with Key Injectable Launch

London, March 25, 2025 – Hikma Pharmaceuticals, a leader in generic injectables, has introduced Cisatracurium Besylate Injection, USP in the United States, available in 200mg/20mL and 20mg/10mL doses. This muscle relaxant is used in surgery and intensive care units (ICUs) to help with tracheal intubation and mechanical ventilation. The launch marks another step in Hikma’s mission to expand access to essential medicines, ensuring hospitals and healthcare providers have reliable treatment options for critical procedures.

With US sales of Cisatracurium Besylate Injection reaching $14 million over the past year, Hikma is reinforcing its position as a top supplier of generic injectables. The company’s growing portfolio of more than 170 products reflects its commitment to delivering high-quality, life-saving medicines. By continually introducing new formulations and essential treatments, Hikma is helping improve patient outcomes and supporting the evolving needs of the healthcare industry.